StreetInsider.com News Articles

Form 144 Emergent BioSolutions Filed by: Williams Paul Anthony

Thu, 01 Oct 2026 16:20:00 -0400

si-local-file:///var/storage/secattach/20261001/27136263.html

Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility

Tue, 15 Sep 2026 07:45:00 -0400

Company leaders, elected officials and community stakeholders will come together on September 16, 2026 to mark milestone in advanced biopharmaceutical manufacturing

CANTON, Mass., Sept. 15, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) will host a ribbon cutting ceremony on Wednesday, September 16 at 10 a.m. ET to celebrate the manufacturing restart and growth of its Canton, Massachusetts facility and the company’s investment in the future of advanced biopharmaceutical manufacturing in the Commonwealth.

The event will highlight Emergent's commitment to strengthening domestic manufacturing capabilities, supporting public health preparedness and creating opportunities for skilled jobs in Massachusetts.

Media Advisory: Emergent to Host Ribbon Cutting Ceremony at Canton Manufacturing Facility

Tue, 15 Sep 2026 07:45:00 -0400

Company leaders, elected officials and community stakeholders will come together on September 16, 2026 to mark milestone in advanced biopharmaceutical manufacturing

Form 8-K Emergent BioSolutions For: Sep 14

Mon, 14 Sep 2026 16:02:00 -0400

si-local-file:///var/storage/secattach/20260914/27058312.html

Emergent BioSolutions buys back $75M in senior unsecured notes

Thu, 03 Sep 2026 07:45:34 -0400

Emergent BioSolutions Inc. (NYSE: EBS) has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028, according to a company statement.

The Gaithersburg, Md.-based company deployed approximately $68 million in cash for the repurchases, at an average price of 90.6% of face value. Following the transactions, the outstanding aggregate principal balance of the Senior Unsecured Notes has been reduced to approximately $364.7 million.

The repurchases were authorized by Emergent's Board of Directors. The company said it plans to monitor market conditions and evaluate the timing for refinancing the remaining outstanding notes, which mature in August

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

Thu, 03 Sep 2026 07:45:00 -0400

Repurchase reduces unsecured note balance to approximately $364.7 million
Management to discuss this key milestone and broader transformation progress at upcoming investor conferences

GAITHERSBURG, Md., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has completed the repurchase of $75 million aggregate principal amount of its 3.875% Senior Unsecured Notes due 2028 (the “Senior Unsecured Notes”), following authorization granted by its Board of Directors. In total, Emergent deployed approximately $68 million of cash for the repurchases, resulting in an average repurchase price of 90.6% of

Emergent BioSolutions Completes Repurchase of $75 Million Aggregate Principal Amount of Senior Unsecured Notes

Thu, 03 Sep 2026 07:45:00 -0400

Repurchase reduces unsecured note balance to approximately $364.7 million
Management to discuss this key milestone and broader transformation progress at upcoming investor conferences

Form 8-K Emergent BioSolutions For: Aug 18

Tue, 01 Sep 2026 16:13:00 -0400

si-local-file:///var/storage/secattach/20260901/27012962.html

Emergent BioSolutions gets $24M BARDA contract for anthrax vaccine

Tue, 01 Sep 2026 07:55:13 -0400

Emergent BioSolutions Inc. (NYSE: EBS) has received a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA) to supply its CYFENDUS® anthrax vaccine, according to a company press release.

BARDA is part of the Administration for Strategic Preparedness and Response within the U.S. Department of Health and Human Services. The contract covers the supply of CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts.

CYFENDUS® received U.S. Food and Drug Administration approval in July 2023 as a two-dose anthrax vaccine for post-exposure prophylaxis in individuals aged 18 through 65 when administered alongside recommended antibacterial drugs.

The

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Tue, 01 Sep 2026 07:55:00 -0400

GAITHERSBURG, Md., Sept. 01, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced a contract modification valued at approximately $24 million from the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS), to supply CYFENDUS^® (Anthrax Vaccine Adsorbed, Adjuvanted) for anthrax preparedness efforts. Anthrax remains a significant global biological threat due to its potential use in a bioterrorism event and its implications for public health and national security.

“This newly executed CYFENDUS^® contract modification with the U.S.

Emergent BioSolutions Awarded Contract Modification Valued at Approximately $24 Million for CYFENDUS® (Anthrax Vaccine Adsorbed, Adjuvanted)

Tue, 01 Sep 2026 07:55:00 -0400

“This newly executed CYFENDUS^® contract modification with the U.S.

Emergent BioSolutions wins Canada NARCAN supply deal through 2029

Mon, 31 Aug 2026 07:55:30 -0400

Emergent BioSolutions Inc. (NYSE: EBS) has been awarded a standing offer by the Government of Canada to supply NARCAN® Nasal Spray, following a competitive procurement process, according to a company press release.

The agreement runs from October 1, 2026, through September 30, 2029, with an option to extend for two additional years. It replaces an existing five-year standing offer set to expire in September 2026.

Under the arrangement, authorized federal departments, agencies, Crown corporations, provinces, territories, and other designated public sector organizations across Canada may purchase NARCAN® Nasal Spray through individual call-ups.

NARCAN® Nasal Spray is a 4 mg intranasal naloxone spray indicated

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

Mon, 31 Aug 2026 07:55:00 -0400

Standing offer expands access to opioid overdose emergency treatment across participating federal, provincial and territorial organizations in Canada

WINNIPEG, Manitoba, Aug. 31, 2026 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE: EBS) today announced that it has been awarded a standing offer by the Government of Canada, through a competitive procurement process, to supply NARCAN® Nasal Spray. The standing offer is effective from October 1, 2026, through September 30, 2029, with an option to extend for an additional two years.

Under the standing offer, authorized federal departments, agencies, Crown corporations, provinces, territories and other designated

Emergent BioSolutions Awarded Government of Canada Standing Offer for NARCAN® Nasal Spray

Mon, 31 Aug 2026 07:55:00 -0400

Standing offer expands access to opioid overdose emergency treatment across participating federal, provincial and territorial organizations in Canada

Under the standing offer, authorized federal departments, agencies, Crown corporations, provinces, territories and other designated

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

Mon, 31 Aug 2026 07:54:00 -0400

Ready to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark
Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning preparedness across Canada

GAITHERSBURG, Md., Aug. 31, 2026 (GLOBE NEWSWIRE) -- In recognition of International Overdose Awareness Day (IOAD), Emergent BioSolutions (NYSE: EBS) is reaffirming its commitment to expanding awareness of opioid overdose risks and increasing preparedness to help save lives. According to the World Health Organization, opioids are associated with nearly 80 percent of drug-related deaths worldwide, highlighting the continued need for education, preparedness and

Emergent BioSolutions Reinforces Commitment to Opioid Overdose Education and Preparedness on International Overdose Awareness Day

Mon, 31 Aug 2026 07:54:00 -0400

Ready to Rescue campaign returns to U.S. college campuses with Release Recovery Founder and CEO Zac Clark
Partnership with professional baseball player Davis Schneider seeks to raise awareness of opioid poisoning preparedness across Canada

JPMorgan Reinstates Emergent BioSolutions (EBS) at Underweight

Fri, 21 Aug 2026 03:28:25 -0400

JPMorgan analyst Jessica Fye reinstates coverage on Emergent BioSolutions (NYSE: EBS) with a Underweight rating.

For an analyst ratings summary and ratings history on Emergent BioSolutions click here. For more ratings news on Emergent BioSolutions click here.

Shares of Emergent BioSolutions closed at $4.82 yesterday.

Form SCHEDULE 13G Emergent BioSolutions Filed by: AMERICAN CENTURY INVESTMENT MANAGEMENT INC

Fri, 14 Aug 2026 14:37:00 -0400

si-local-file:///var/storage/secattach/20260814/26929075.html

Form SCHEDULE 13G Emergent BioSolutions Filed by: AMERICAN CENTURY INVESTMENT MANAGEMENT INC

Fri, 14 Aug 2026 14:37:00 -0400

si-local-file:///var/storage/secattach/20260814/26929075.html

Form 3 Emergent BioSolutions For: Aug 05 Filed by: Duatschek Stephanie

Wed, 12 Aug 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26910012.html

Form 3 Emergent BioSolutions For: Aug 05 Filed by: Duatschek Stephanie

Wed, 12 Aug 2026 09:17:00 -0400

si-local-file:///var/storage/secattach/20260812/26910012.html

Emergent BioSolutions (EBS) PT Lowered to $10 at H.C. Wainwright

Mon, 10 Aug 2026 06:52:57 -0400

(Updated - August 10, 2026 6:52 AM EDT)

H.C. Wainwright analyst Raghuram Selvaraju lowered the price target on Emergent BioSolutions (NYSE: EBS) to $10.00 (from $12.00) while maintaining a Buy rating.

The analyst commented: "Late last week, Emergent BioSolutions reported its 2Q26 financial results. The company recorded $234.3M in top-line revenue for the period, well ahead of guidance and soundly beating our forecast for top-line revenue totaling only $175M. However, Emergent lowered its full-year 2026 revenue guidance to $645-675M vs. the prior guidance range of $720-760M. This is driven mainly by the outlook for the naloxone franchise, which is slated to undergo